⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 7, 2024The OncologistOpen Access

Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib

Kai‐Yuan Hsiao Hsin‐Pao Chen Kun-Ming Rau Kuang-Wen Liu Ben‐Chang Shia Wei-Shan Chang Hao-Yun Liang Meng‐Che Hsieh

View Full Paper

Ask AI

Bookmark

Share

Abstract

The impact of sidedness on survival of later-line treatment in patients with metastatic colorectal cancer (mCRC) is undetermined. This study aimed to investigate the association between sidedness and survival among chemotherapy refractory patients with mCRC treated with trifluridine/tipiracil (TAS-102) or regorafenib or both.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hsiao et al. (2024) studied this question.

synapsesocial.com/papers/68e591fdb6db64358752d2b6 https://doi.org/10.1093/oncolo/oyae235

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer: a population-wide cohort study2024 · 1 citations
2Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study2024 · 11 citations
3Regorafenib combined with trifluridine/tipiracil versus regorafenib monotherapy in refractory metastatic colorectal cancer (FDZL-REGOT): A randomized phase 2 trial.Late-Phase Clinical Trial · 2026
4Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal CancerOriginal Research · 2026
5Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancerOriginal Research · 2026 · 1 citations